James F. Reddoch - Jun 4, 2021 Form 4 Insider Report for Royalty Pharma plc (RPRX)

Signature
/s/ Jason Mehar, as Attorney-in-Fact for James F. Reddoch
Stock symbol
RPRX
Transactions as of
Jun 4, 2021
Transactions value $
-$9,110,689
Form type
4
Date filed
6/8/2021, 08:12 PM
Previous filing
Jun 4, 2021
Next filing
Jul 8, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RPRX Class A Ordinary Shares Sale -$4.46M -100K -6.8% $44.60 1.37M Jun 4, 2021 By Reddoch RPI LLC F1
transaction RPRX Class A Ordinary Shares Sale -$2.23M -47.8K -3.49% $46.57 1.32M Jun 7, 2021 By Reddoch RPI LLC F2
transaction RPRX Class A Ordinary Shares Sale -$104K -2.21K -0.17% $47.01 1.32M Jun 7, 2021 By Reddoch RPI LLC F3
transaction RPRX Class A Ordinary Shares Sale -$2.32M -50K -3.79% $46.43 1.27M Jun 8, 2021 By Reddoch RPI LLC F4
holding RPRX Class A Ordinary Shares 25K Jun 4, 2021 By IRA
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.14 to $45.06 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.00 to $46.99 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Such transactions were effected pursuant to a 10b5-1 plan adopted by the reporting person on December 30, 2020.
F3 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.00 to $47.02 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Such transactions were effected pursuant to a 10b5-1 plan adopted by the reporting person on December 30, 2020.
F4 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.30 to $46.67 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.